Exelixis, Inc. EXEL
We take great care to ensure that the data presented and summarized in this overview for EXELIXIS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EXEL
View all-
Black Rock Inc. New York, NY33.5MShares$1.48 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.26 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$993 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$653 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$520 Million0.02% of portfolio
-
Lsv Asset Management Chicago, IL8.16MShares$360 Million0.72% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA7.8MShares$344 Million1.13% of portfolio
-
Geode Capital Management, LLC Boston, MA7.42MShares$327 Million0.02% of portfolio
-
Aqr Capital Management LLC Greenwich, CT6.89MShares$304 Million0.27% of portfolio
-
Invesco Ltd. Atlanta, GA5.57MShares$246 Million0.04% of portfolio
Latest Institutional Activity in EXEL
Top Purchases
Top Sells
About EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Insider Transactions at EXEL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 03
2025
|
Jack L Wyszomierski Director |
SELL
Open market or private sale
|
Direct |
7,535
-2.06%
|
$324,005
$43.09 P/Share
|
Jun 02
2025
|
Sue Gail Eckhardt Director |
SELL
Open market or private sale
|
Direct |
18,838
-23.42%
|
$810,034
$43.21 P/Share
|
May 29
2025
|
Bob Oliver Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+18.47%
|
-
|
May 29
2025
|
Mary C Beckerle Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+19.61%
|
-
|
May 29
2025
|
Julie Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+32.27%
|
-
|
May 29
2025
|
Sue Gail Eckhardt Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+19.61%
|
-
|
May 29
2025
|
Stelios Papadopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+0.76%
|
-
|
May 29
2025
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+8.87%
|
-
|
May 29
2025
|
Jack L Wyszomierski Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+2.61%
|
-
|
May 29
2025
|
George Poste Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+5.2%
|
-
|
May 29
2025
|
Tomas J. Heyman Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,812
+18.84%
|
-
|
May 21
2025
|
Tomas J. Heyman Director |
SELL
Open market or private sale
|
Direct |
4,544
-12.28%
|
$199,936
$44.29 P/Share
|
May 20
2025
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
34,387
-7.7%
|
$1,513,028
$44.06 P/Share
|
May 16
2025
|
Amy C. Peterson EVP Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
72,776
-13.52%
|
$3,274,920
$45.47 P/Share
|
May 16
2025
|
Amy C. Peterson EVP Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+6.92%
|
$840,000
$21.75 P/Share
|
May 16
2025
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
87,871
+4.53%
|
-
|
May 16
2025
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
87,871
-5.47%
|
-
|
May 16
2025
|
Christopher J. Senner EVP and CFO |
SELL
Open market or private sale
|
Direct |
100,000
-9.36%
|
$4,600,000
$46.0 P/Share
|
May 16
2025
|
Christopher J. Senner EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+8.56%
|
$1,800,000
$18.8 P/Share
|
May 16
2025
|
George Poste Director |
SELL
Open market or private sale
|
Direct |
20,634
-10.88%
|
$928,530
$45.99 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 2.85M shares |
---|---|
Exercise of conversion of derivative security | 1.96M shares |
Bona fide gift | 462K shares |
Open market or private sale | 1.5M shares |
---|---|
Payment of exercise price or tax liability | 1.65M shares |
Bona fide gift | 523K shares |
Other acquisition or disposition | 4.68K shares |